Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study
The objective of the study was to investigate the response rate to non-steroidal anti-inflammatory drugs (NSAIDs) and the clinical parameters that might predict this response in patients with active ankylosing spondylitis. This is a prospective, observational, 3-month study that was conducted in a single center. Ninety-five consecutive patients with active ankylosing spondylitis were included in the study. Full dose NSAIDs (indometacin 150 mg daily or acemethazine 180 mg daily) were given to patients. Relevant clinical data of all patients’ were recorded at the beginning and on three consecutive monthly visits. At the end of the study period, patients who respond to NSAIDs were determined. Demographic, clinical, and laboratory parameters that might influence the response to the NSAIDs were investigated. The response rate to the full-dose NSAIDs according to the ASAS20 in patients with active ankylosing spondylitis was found as 29.5%. Similarly, 20.0% of the patients were responders according to the ASAS40 criteria, whereas 5.6% of the patients responded according to the 5-out-of-6 criteria at week 12. Patients who responded to the treatment were found to be younger at the study entry (P = 0.001) and had shorter disease duration (P < 0.001). Due to the markedly lower rate of response to the NSAIDs in patients with active ankylosing spondylitis, early identification of those patients who does not respond to NSAIDs and subsequent decision regarding the institution of second-line treatments (anti-TNF) may be of great value in the prevention of irreversible changes that might develop in most of the patients.
KeywordsAnkylosing spondylitis Non-steroidal anti-inflammatory drugs Therapy
The authors thank Yavuz Sanisoglu, PhD, as well as clinical members of the Division of Rheumatology, Gulhane School of Medicine, for assistance with the conduct of the study.
- 5.Dougados M, Béhier JM, Jolchine I et al (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor in the treatment of ankylosing spondylitis. A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44(1):180–185. doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K CrossRefPubMedGoogle Scholar
- 8.Dougados M, Dijkmans B, Khan M et al (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61:40–50Google Scholar
- 22.Khan MA (2003) Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weicman ME (eds) Rheumatology, 3rd edn. Mosby, Spain, pp 1161–1181Google Scholar
- 24.Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F CrossRefPubMedGoogle Scholar
- 34.Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) Assessment in AS’ international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442–452. doi: 10.1136/ard.2005.041137 CrossRefPubMedGoogle Scholar
- 35.Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236. doi: 10.1002/art.11325 CrossRefPubMedGoogle Scholar
- 37.van der Heijde D, Kivitz A, Schiff MH et al (ATLAS Study Group) (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146. doi: 10.1002/art.21913 CrossRefPubMedGoogle Scholar
- 38.Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12):1558–1565. doi: 10.1093/rheumatology/kel149 CrossRefGoogle Scholar